Dynacure Receives Fast Track Designation for DYN101, an Investigational Antisense Oligonucleotide for the Treatment of Myotubular and Centronuclear Myopathies
STRASBOURG, Pa., Jan. 6, 2022 /PRNewswire/ -- Dynacure, a clinical stage biotechnology company focusing on Myotubular and Centronuclear Myopathies (CNM), a group of rare, debilitating, and life-threatening genetic diseases, today announced that the U.S.
PR NewswireJan 6, 2022 16:12 ET
Dynacure to Present at 40th Annual J.P. Morgan Healthcare Conference
STRASBOURG, France and PHILADELPHIA, Jan. 3, 2022 /PRNewswire/ -- Dynacure, a clinical stage biotechnology company focusing on Myotubular and Centronuclear Myopathies (CNM), a group of rare, debilitating and life-threatening genetic diseases, today anno
PR NewswireJan 3, 2022 16:12 ET
BRIEF-Dynacure Announces Strategic Collaboration And Option Agreement With Nippon Shinyaku
Nov 10 (Reuters) - Dynacure Sa DYCU.O :* DYNACURE ANNOUNCES STRATEGIC COLLABORATION AND OPTION AGREEMENT WITH NIPPON SHINYAKU* NIPPON SHINYAKU SECURES AN EXCLUSIVE OPTION TO ACQUIRE ALL DEVELOPMENT A
reutersNov 10, 2021 03:06 ET
NASDAQ TRADE HALT DYCU.O REASON NOT AVAILABLE AT 04:00 AM
NASDAQ TRADE HALT REASON NOT AVAILABLE AT 04:00 A
路透社Jul 14, 2021 04:00 ET
No Data
No Data